Bayer's $2.2 Billion Ohio Plant and BlueRock's Orphan Drug Nod: Two Fronts in a Shifting US Pharma Landscape
Published on 10/04/2026 at 06:01 | Editorial boerse-global.de
Washington's hardening trade posture is redrawing the map for global drugmakers, and Bayer is responding with both bricks and regulatory filings. On one side of the Atlantic, the Leverkusen-based group is committing $2.2 billion to a new pharmaceutical production site in New Albany, Ohio. On the other, its BlueRock Therapeutics subsidiary has secured orphan drug designations on both sides of the Atlantic for a cell therapy candidate.
Tariff Pressure Reshapes Manufacturing Calculus
President Trump has turned up the heat on foreign manufacturers, slapping tariffs on select patented medicines produced outside the United States, with duties on generic imports slated for 2028. Companies that build plants on American soil are set to face lower tariff rates than those that rely purely on imports. Trump has credited his tariff policy with sparking more than $600 billion in new pharma investment. At the same time, his administration is pressing for markedly lower domestic drug prices, noting that US patients often pay nearly three times what people in other industrialized nations pay for the same treatments.
Against that backdrop, local production capacity has become a strategic imperative rather than a nice-to-have.
A 200-Acre Campus in Ohio
Bayer's answer is a 200-acre campus in New Albany that will churn out both active pharmaceutical ingredients and finished medicines, with a focus on oncology as well as cardiovascular and kidney disease. CEO Bill Anderson called the project a historic investment and stressed the importance of the US as both a manufacturing base and an innovation hub. Ohio Governor Mike DeWine framed the arrival as a record investment from Germany for his state.
Should investors sell immediately? Or is it worth buying Bayer?
The build-out is a long game. The first phase is scheduled to come online in 2031, with the second following in 2034. Once fully operational, the site is expected to support roughly 600 permanent, skilled positions.
The move builds on a deep existing footprint. According to DPA, Bayer poured more than $7 billion into US pharmaceutical research, development and production in the five years preceding this project. Strengthening regional manufacturing is intended to cut cross-border dependencies and make supply chains more resilient.
Pipeline and Personnel Moves Run in Parallel
While the Ohio shovels are still to hit the ground, Bayer has been busy reshaping its core prescription medicines business. On Thursday, the company named Dr. Christoph Koenen as Chief Medical Officer of its pharma division, effective October 1. Koenen will hold the role in addition to his existing duties as head of clinical development and operations — a consolidation that puts strategic development programs under a single roof.
Regulatory progress has followed. BlueRock Therapeutics reported on Wednesday that its product candidate Lemiretprocel, designated OpCT-001, received orphan drug status from both the US Food and Drug Administration and the European Medicines Agency for certain inherited retinal diseases. The designation is designed to spur therapies for rare conditions and gives developers procedural support in further clinical trials.
Portfolio Pruning and a Fresh Capital Raise
Those steps sit alongside a broader tidying of the portfolio. On September 21, Bayer agreed to sell the rights to its cancer drug Stivarga to pharmaceutical company Grünenthal for up to EUR 375 million, with the deal expected to close at the end of 2026 or early 2027. Two days later, on September 23, management shored up the balance sheet by placing EUR 2 billion in hybrid bonds across two separate tranches, lifting the total outstanding volume of these subordinated notes to EUR 6.55 billion.
Shares Under Pressure Despite Year-to-Date Gains
The equity has nonetheless been on the back foot. Bayer stock closed Friday's session at EUR 45.02, a decline of 10% over the trailing seven days. Since the start of the year, however, the shares remain firmly in positive territory, up 22%.
Ad
Bayer Stock: New Analysis - 4 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
